CR11053A - Compuestos heterociclicos y sus usos - Google Patents

Compuestos heterociclicos y sus usos

Info

Publication number
CR11053A
CR11053A CR11053A CR11053A CR11053A CR 11053 A CR11053 A CR 11053A CR 11053 A CR11053 A CR 11053A CR 11053 A CR11053 A CR 11053A CR 11053 A CR11053 A CR 11053A
Authority
CR
Costa Rica
Prior art keywords
inflammatory
disorders
autoimmune
arthritis
conditions
Prior art date
Application number
CR11053A
Other languages
English (en)
Inventor
Yi Chen
Timothy D Cushing
Jason A Duquette
Lopez De Turiso Felix Gonzalez
Xiaolin Hao
Xiao He
Brian Lucas
Lawrence R Mcgee
Andreas Reichelt
Robert M Rzasa
Jennifer Seganish
Youngsook Shin
Dawei Zhang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR11053A publication Critical patent/CR11053A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Abstract

Se describen heteroarilos biciclicos sustituidos y composiciones que los contienen para el tratamiento de inflamacion general, artritis, enfermedades reumaticas, osteoartritis, trastornos inflamatorios del intestino, trastornos inflamatorios oculares, trastornos inflamatorios o de vejiga inestable, psoriasis, problemas de la piel con componentes inflamatorios, condiciones inflamatorias cronicas, que incluyen pero no estan restringidas a, enfermedades autoinmunes tales como lupus eritematoso sistemico (LES), miastenia grave, artritis reumatoide, encefalomielitis diseminada aguda, purpura trombocitopenica idiopatica, esclerosis multiple, sindrome de Sjoegren y anemia hemolitica autoinmune, condiciones alergicas incluyendo todas las formas de hipersensibilidad.
CR11053A 2007-03-23 2009-10-05 Compuestos heterociclicos y sus usos CR11053A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91956807P 2007-03-23 2007-03-23

Publications (1)

Publication Number Publication Date
CR11053A true CR11053A (es) 2009-10-23

Family

ID=39645618

Family Applications (2)

Application Number Title Priority Date Filing Date
CR11053A CR11053A (es) 2007-03-23 2009-10-05 Compuestos heterociclicos y sus usos
CR11582A CR11582A (es) 2007-03-23 2010-07-21 Compuestos heterociclicos y sus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR11582A CR11582A (es) 2007-03-23 2010-07-21 Compuestos heterociclicos y sus usos

Country Status (24)

Country Link
US (6) US8193199B2 (es)
EP (2) EP2137186B1 (es)
JP (2) JP5527761B2 (es)
KR (1) KR101504773B1 (es)
CN (1) CN101715453B (es)
AU (1) AU2008231304B2 (es)
BR (1) BRPI0809141A2 (es)
CA (1) CA2681136C (es)
CR (2) CR11053A (es)
DK (1) DK2137186T3 (es)
EA (1) EA017389B1 (es)
ES (1) ES2563458T3 (es)
HR (1) HRP20160350T1 (es)
HU (1) HUE028954T2 (es)
IL (1) IL200867A (es)
MX (1) MX2009009968A (es)
NZ (1) NZ579834A (es)
PL (1) PL2137186T3 (es)
PT (1) PT2137186E (es)
RS (1) RS54706B1 (es)
SI (1) SI2137186T1 (es)
UA (1) UA98955C2 (es)
WO (1) WO2008118468A1 (es)
ZA (1) ZA201308294B (es)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
CA2647391C (en) 2006-04-04 2015-12-29 The Regents Of The University Of California Kinase antagonists
EP2139882B1 (en) * 2007-03-23 2013-12-25 Amgen Inc. 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
PT2137186E (pt) * 2007-03-23 2016-03-30 Amgen Inc Compostos heterocíclicos e suas utilizações
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US8399483B2 (en) 2007-12-21 2013-03-19 Ucb Pharma S.A. Quinoxaline and quinoline derivatives as kinase inhibitors
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009155121A2 (en) 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
WO2010006086A2 (en) 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
CA2738429C (en) * 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
EP2358720B1 (en) 2008-10-16 2016-03-02 The Regents of The University of California Fused ring heteroaryl kinase inhibitors
GB0819593D0 (en) 2008-10-24 2008-12-03 Ucb Pharma Sa Therapeutic agents
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
GB0821693D0 (en) * 2008-11-27 2008-12-31 Ucb Pharma Sa Therapeutic agents
WO2010093808A1 (en) * 2009-02-11 2010-08-19 Reaction Biology Corp. Selective kinase inhibitors
US8513284B2 (en) 2009-02-13 2013-08-20 Ucb Pharma, S.A. Fused pyridine and pyrazine derivatives as kinase inhibitors
EP2403847B1 (en) 2009-03-06 2016-03-02 UCB Biopharma SPRL Triazine derivatives as kinase inhibitors
US20120071475A1 (en) 2009-04-27 2012-03-22 Shionogi & Co., Ltd. Urea derivatives having pi3k-inhibiting activity
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
GB0908957D0 (en) * 2009-05-22 2009-07-01 Ucb Pharma Sa Therapeutic agents
TW201111362A (en) * 2009-06-25 2011-04-01 Amgen Inc Heterocyclic compounds and their uses
AR077280A1 (es) 2009-06-29 2011-08-17 Incyte Corp Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
EP2499126B1 (en) 2009-11-12 2015-01-07 UCB Pharma, S.A. Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors
ES2442369T3 (es) 2009-11-12 2014-02-11 Ucb Pharma, S.A. Derivados de quinolina y quinoxalina como inhibidores de cinasa
WO2011058109A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
WO2011058108A1 (en) * 2009-11-12 2011-05-19 Ucb Pharma S.A. Quinoline and quinoxaline derivatives as kinase inhibitors
WO2011058111A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Aminopurine derivatives as kinase inhibitors
WO2011058112A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrazole derivatives as kinase inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011075630A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
AU2010330875B2 (en) * 2009-12-18 2013-08-01 Amgen Inc. Heterocyclic compounds and their uses
WO2011093365A1 (ja) * 2010-01-27 2011-08-04 協和発酵キリン株式会社 含窒素複素環化合物
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
JP2013533883A (ja) * 2010-06-30 2013-08-29 アムジエン・インコーポレーテツド ＰＩ３Ｋδ阻害剤としての含窒素複素環化合物
WO2012003262A1 (en) * 2010-07-01 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
US20130085131A1 (en) * 2010-07-01 2013-04-04 Amgen Inc. Heterocyclic compounds and their uses
MX2012015134A (es) 2010-07-02 2013-05-06 Amgen Inc Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k.
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
US9670212B2 (en) 2010-09-14 2017-06-06 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
AU2011323243A1 (en) * 2010-11-04 2013-05-23 Amgen Inc. Heterocyclic compounds and their uses
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2816144A1 (en) * 2010-11-17 2012-05-24 Amgen Inc. Quinoline derivatives as pik3 inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
EP2751093A1 (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SI2751109T1 (sl) 2011-09-02 2017-03-31 Incyte Holdings Corporation Heterociklilamini kot inhibitorji pi3k
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
CA2850166C (en) 2011-09-27 2019-12-03 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
EP2763994A4 (en) * 2011-10-04 2015-08-26 Gilead Calistoga Llc NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
DK2790705T3 (en) 2011-12-15 2018-03-12 Novartis Ag Use of inhibitors of the activity or function of PI3K
US20150011569A1 (en) * 2011-12-15 2015-01-08 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
BR112015006828A8 (pt) 2012-09-26 2019-09-17 Univ California composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
TWI631105B (zh) * 2013-01-31 2018-08-01 維泰克斯製藥公司 作爲鈉通道調節劑之喹啉及喹噁啉醯胺
MX362896B (es) 2013-02-19 2019-02-22 Amgen Inc Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
JP6377123B2 (ja) 2013-03-14 2018-08-22 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4039256A1 (en) 2013-11-11 2022-08-10 Amgen Inc. Combination therapy including an mdm2 inhibitor and dasatinib or nilotinib for the treatment of chronic myeloid leukemia
US10328080B2 (en) 2013-12-05 2019-06-25 Acerta Pharma, B.V. Therapeutic combination of PI3K inhibitor and a BTK inhibitor
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015171725A1 (en) 2014-05-06 2015-11-12 Amgen Inc. Hydrate, crystalline hydrate and crystalline anhydrate forms of n-((1s)-1-(7-fluoro-2-(2-pyridinyl)-3-quinolinyl)ethyl)-9h-purin-6-amine, pharmaceutical compositions containing them and methods for treating cancer.
CN104086551B (zh) * 2014-06-06 2016-09-21 人福医药集团股份公司 化合物及其制备方法和用途
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016001855A1 (en) 2014-07-04 2016-01-07 Lupin Limited Quinolizinone derivatives as pi3k inhibitors
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
HRP20211813T1 (hr) 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
ES2921875T3 (es) 2014-08-11 2022-09-01 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor BTK, un inhibidor PD-1 y/o un inhibidor PD-L1
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
EP3206689B1 (en) 2014-10-14 2021-12-08 La Jolla Institute of Allergy & Immunology Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
WO2016115434A1 (en) 2015-01-16 2016-07-21 The General Hospital Corporation Compounds for improving mrna splicing
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
CN117800973A (zh) 2015-02-27 2024-04-02 因赛特控股公司 Pi3k抑制剂的盐及其制备方法
CN106008479B (zh) 2015-03-06 2020-01-10 南京圣和药业股份有限公司 作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用
GB201506786D0 (en) * 2015-04-21 2015-06-03 Ucb Biopharma Sprl Therapeutic use
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10045981B2 (en) 2015-11-24 2018-08-14 Jakpharm, Llc Selective kinase inhibitors
CN108290898B (zh) * 2016-03-05 2020-09-08 杭州征祥医药有限公司 作为磷脂酰肌醇3-激酶抑制剂的喹啉类似物
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN108069899B (zh) * 2016-11-18 2021-01-08 中国科学院大连化学物理研究所 一种制备2,3-取代喹啉类衍生物的方法
WO2018204176A1 (en) 2017-05-01 2018-11-08 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
US10442799B1 (en) 2018-04-07 2019-10-15 Fuqiang Ruan Heterocyclic compounds and uses thereof
EP3788038B1 (en) 2018-05-04 2023-10-11 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms
WO2021057696A1 (zh) * 2019-09-27 2021-04-01 隆泰申医药科技(南京)有限公司 一种杂芳基类化合物及其应用
EP4045047A1 (en) 2019-10-15 2022-08-24 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
US20230028414A1 (en) 2019-12-16 2023-01-26 Amgen Inc. Dosing regimen of kras g12c inhibitor
CN114276326B (zh) * 2021-03-09 2022-11-11 南京征祥医药有限公司 喹啉化合物的盐及制备方法和应用
CN113218936B (zh) * 2021-06-07 2021-09-10 江苏欣诺科催化剂有限公司 锇酸钾的纯度检测方法
WO2023016477A1 (en) * 2021-08-11 2023-02-16 Taizhou Eoc Pharma Co., Ltd. A cyclin-dependent kinase inhibitor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
US5822910A (en) 1997-10-02 1998-10-20 Shewmake; I. W. Fishing line tensioning device
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
US20050165029A1 (en) * 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
ATE524467T1 (de) * 2005-04-25 2011-09-15 Merck Patent Gmbh Neuartige aza-heterozyklen als kinase-inhibitoren
EP1993537A4 (en) 2006-03-02 2010-05-19 Glaxosmithkline Llc THIAZOLONES AS INHIBITORS OF P13-KINASES
EP1996191A4 (en) 2006-03-02 2010-05-19 Glaxosmithkline Llc THIAZOLONE AS A PI3 KINASE INHIBITOR
WO2008097976A1 (en) 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
PT2137186E (pt) 2007-03-23 2016-03-30 Amgen Inc Compostos heterocíclicos e suas utilizações
KR20100058530A (ko) 2007-09-26 2010-06-03 아스테라스 세이야쿠 가부시키가이샤 퀴놀론 유도체
US8399483B2 (en) * 2007-12-21 2013-03-19 Ucb Pharma S.A. Quinoxaline and quinoline derivatives as kinase inhibitors
CA2738429C (en) * 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
GB0819593D0 (en) * 2008-10-24 2008-12-03 Ucb Pharma Sa Therapeutic agents
GB0821693D0 (en) * 2008-11-27 2008-12-31 Ucb Pharma Sa Therapeutic agents
US8513284B2 (en) * 2009-02-13 2013-08-20 Ucb Pharma, S.A. Fused pyridine and pyrazine derivatives as kinase inhibitors
JP5789252B2 (ja) * 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
TW201111362A (en) * 2009-06-25 2011-04-01 Amgen Inc Heterocyclic compounds and their uses
EP2499126B1 (en) 2009-11-12 2015-01-07 UCB Pharma, S.A. Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors
AU2010330875B2 (en) 2009-12-18 2013-08-01 Amgen Inc. Heterocyclic compounds and their uses

Also Published As

Publication number Publication date
EP2137186B1 (en) 2016-01-27
AU2008231304B2 (en) 2011-05-12
JP2010522179A (ja) 2010-07-01
JP5527761B2 (ja) 2014-06-25
UA98955C2 (ru) 2012-07-10
CN101715453B (zh) 2012-06-27
US20090137581A1 (en) 2009-05-28
ES2563458T3 (es) 2016-03-15
JP5819382B2 (ja) 2015-11-24
US20120220585A1 (en) 2012-08-30
RS54706B1 (en) 2016-08-31
PT2137186E (pt) 2016-03-30
HUE028954T2 (en) 2017-01-30
CR11582A (es) 2011-01-10
US20180105532A1 (en) 2018-04-19
EP3045458A1 (en) 2016-07-20
BRPI0809141A2 (pt) 2014-08-26
NZ579834A (en) 2012-03-30
WO2008118468A1 (en) 2008-10-02
US8901135B2 (en) 2014-12-02
MX2009009968A (es) 2009-10-08
US9873701B2 (en) 2018-01-23
CA2681136C (en) 2012-05-22
US8586739B2 (en) 2013-11-19
EP2137186A1 (en) 2009-12-30
AU2008231304A1 (en) 2008-10-02
EA017389B1 (ru) 2012-12-28
KR101504773B1 (ko) 2015-03-20
US20150045361A1 (en) 2015-02-12
IL200867A (en) 2014-11-30
EA200901276A1 (ru) 2010-04-30
DK2137186T3 (en) 2016-04-18
HRP20160350T1 (hr) 2016-05-06
JP2014058526A (ja) 2014-04-03
US8193199B2 (en) 2012-06-05
SI2137186T1 (sl) 2016-04-29
CA2681136A1 (en) 2008-10-02
ZA201308294B (en) 2014-07-30
US20200048265A1 (en) 2020-02-13
PL2137186T3 (pl) 2016-09-30
US20120220586A1 (en) 2012-08-30
CN101715453A (zh) 2010-05-26
KR20100015795A (ko) 2010-02-12
IL200867A0 (en) 2010-05-17

Similar Documents

Publication Publication Date Title
CR11053A (es) Compuestos heterociclicos y sus usos
CR20140503A (es) Compuestos heterociclicos y sus usos
CO6630161A2 (es) Compuestos heterocíclicos y sus usos
EA201270051A1 (ru) Гетероциклические соединения и их применения
ECSP20018586A (es) Compuestos que contienen pirazolopirimidinona y sus usos
CO2018002822A2 (es) Compuestos deuterados y usos de los mismos
CO2020010188A2 (es) Anticuerpos agonistas contra pd-1 y usos de estos
EA201270013A1 (ru) Гетероциклические соединения и их применение
CL2017000372A1 (es) Composiciones novedosas, usos y métodos para hacerlas.
NI201500117A (es) Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos.
UY33728A (es) ?VARIANTES DE Fc SILENCIOSAS DE LOS ANTICUERPOS ANTI-CD40?.
CU24516B1 (es) Derivados aromáticos de sulfonamida útiles como medicamentos contra enfermedades asociadas con dolor
DOP2009000275A (es) Acidos benzoilamino-indan-2-carboxilicos sustituidos y compuestos relacionados
AR068354A1 (es) Anticuerpos contra el receptor del linfona de burkitt (anti- cxcr5) humanizados, derivados de los mismos y su uso
CL2017002106A1 (es) Anticuerpos contra tau y sus usos
CL2011002745A1 (es) Compuestos derivados de acidos grasos poliinsaturados; metodo de preparacion; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de trastornos cardiovasculares, metabolicos e inflamatorios, tales como, artritis reumatoide, aterosclerosis, diabetes, dislipidemia, entre otras.
CL2016002615A1 (es) Heterociclil-sulfonas sustituidas con heteroarilo y su uso contra el dolor, accidente cerebrovascular, transtornos anímicos, epilepsia, esquizofrenia y trastornos neurodegenerativos.
NI200700010A (es) Moduladores de los receptores de alfa 7 acetilcolina nicotinica y sus usos terapéuticos
CL2018000400A1 (es) Heteroarilos sustituidos con pirazolilo y su uso como medicamentos.
CL2013003512A1 (es) Compuestos derivados de 7-(heterociclilo, arilo o heteroarilo) de piridopirazinas o sus sales; composicion farmaceutica que los comprende, utiles para el tratamiento de una enfermedad mediada por ptk quinasa tales como asma alergica, rinitis alergica, artritis reumatoide, esclerosis multiple, lupus, leucopenia, entre otras enfermedades.
UY35311A (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica
UY35357A (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa n eutrofílica
AR117566A1 (es) Anticuerpos anti-trem-1 y sus usos
CL2017002405A1 (es) Compuestos bicíclicos fusionados, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades o desordenes relacionados con el fxr.
CL2016001803A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados, agonistas rxr; composición farmacéutica y su uso en el tratamiento del cáncer, diabetes, obesidad, dermatitis, psoriasis, alopecia, queratosis actínica, enfermedades cardiovasculares, metabólicas, hepáticas, cirrosis, enfermedades renales, fibrosis pulmonar, enfermedades oftálmicas, autoinmunes e inflamatorias, alzheimer, párkinson, esclerosis múltiple.